

The dose-response relationship and gender differences of serum uric acid with total cholesterol: a cross-sectional study

Leilei Guo¹ , Lina Cai¹, Li Hu¹ and
Yueshan Zhou¹

Abstract

Objective: To explore the dose-response relationship and gender differences between serum uric acid (SUA) and total cholesterol (TC) in Chinese individuals.

Methods: This cross-sectional study included secondary data of Chinese adults, collected between 2010 and 2018. The exposure variable was SUA, the outcome variable was TC, and participants were split into five quantiles by SUA levels (Q1 [men, ≤ 283 ; women, ≤ 223] to Q5 [men, ≥ 416 ; women, ≥ 332]). Covariates included age, gender, laboratory and examination information. Multivariable linear regression and subgroup analysis were performed to examine the independent association between SUA and TC. Smooth curve fitting and threshold effect analysis was employed to assess potential non-linear relationships. Additionally, a sensitivity analysis was conducted to validate the robustness of the findings.

Results: The analysis included 6119 participants, of whom, 4078 (66.6%) were female, with a mean age of 63.7 years. After adjusting for potential confounders, SUA showed a significant association with TC in both men ($\beta = 0.09$; 95% confidence interval [CI] 0.05, 0.14) and women ($\beta = 0.13$; 95% CI 0.10, 0.17). The Q5 group exhibited higher TC levels than the Q1 group in both men ($\beta = 0.26$; 95% CI 0.16, 0.37) and women ($\beta = 0.25$, 95% CI 0.17, 0.32). In women, there was an inverted L-shaped relationship between SUA and TC with an inflection point at 359.962 $\mu\text{mol/L}$, whereas a linear relationship was exhibited in men. Subgroup analysis showed no significant interactions in men. Sensitivity analyses confirmed the robustness of the findings.

Conclusions: Significant sex differences and dose-response relationships exist between SUA and TC in the Chinese population. The study may provide new insights into cholesterol management.

Corresponding author:

Leilei Guo, Department of Cardiology, Jiangyou People's Hospital, 30 Middle Section of Monument Street, Zhongba Town, Mianyang, Sichuan Province, 621700, China.
Email: guoleilei1984@163.com

¹Department of Cardiology, Jiangyou People's Hospital, Mianyang, Sichuan, China



Keywords

Serum uric acid, total cholesterol, sex differences, dose-response relationship, cross-sectional study

Date received: 14 October 2024; accepted: 17 January 2025

Introduction

Blood lipids are the total cholesterol (TC), triglycerides and various lipids, such as phospholipids, found in serum. Of these, cholesterol and triglycerides are the lipids most closely associated with clinical disease. Hypercholesterolemia is the most common type of lipid abnormality, characterized by a TC level $\geq 6.22 \mu\text{mol/L}$ ($\geq 240 \text{ mg/dL}$).¹ Both genetic and non-genetic factors (such as diabetes, obesity or unhealthy lifestyle) contribute to the development of hypercholesterolemia, with the latter being more common.² The age-standardized mortality rate from coronary heart disease in the USA showed a downward trend from 1968 throughout the remainder of the 20th century, with a decline of more than 40% from 1980 to 2000, of which, the contribution of risk-factor control accounted for 44%, with the largest contribution coming from the reduction of TC levels, accounting for 24%.³ However, the prevalence of blood lipid abnormalities among Chinese adults has remained high in recent years.⁴ The results of a national survey showed that the overall prevalence of blood lipid abnormalities in adults aged ≥ 18 years was 35.6%, with the most significant increase being the prevalence of hypercholesterolemia.⁵ The awareness, treatment and control rates of blood lipid abnormalities among the Chinese population are low.⁶ Therefore, China is facing a continuous increase in the burden of atherosclerotic cardiovascular disease,⁷ and lipid management is urgently needed.

Serum uric acid (SUA) is a metabolic byproduct of purine nucleotides in the

body. About 80% of purines come from cell metabolism, while 20% are from food. The liver metabolizes purines into SUA, which is then excreted by the kidneys and intestines.⁸ Hyperuricemia is usually defined as SUA level $> 420 \mu\text{mol/L}$ (7 mg/dL),⁹ and is often caused by disorders of purine metabolism and/or decreased SUA excretion. Rapid economic development and significant lifestyle changes have markedly increased the prevalence of hyperuricemia and gout in China.¹⁰ Currently, hyperuricemia affects 13.3% of the population, while gout prevalence ranges from 1% to 3% and continues to rise annually.¹¹ Hyperuricemia is closely associated with the onset and development of cardiovascular and cerebrovascular disease.^{12,13}

Previous studies have shown a positive correlation between hyperuricemia and TC;¹⁴ this association appears to be consistent across different age groups,^{15–17} and is particularly significant in patients with gout and metabolic syndrome. However, research in the general population is limited. Additionally, the association between hyperuricemia and TC remains unclear regarding differences in gender. Firstly, gender differences in SUA levels and TC are conflicting in previous studies.^{18,19} Secondly, gender differences and the dose-response relationship between SUA and TC in the general population are not well understood.^{20,21} Therefore, it remains important to investigate the relationship between gender differences in SUA and TC in the general population. The aim of the present study was to examine gender differences and the dose-response

relationship between SUA levels and TC utilizing baseline data from a large community survey in southeastern China.

Participants and methods

Study population and study design

The original data for this cross-sectional study were collected from communities in southeastern China between 2010 and 2018, as previously described by Luo et al.²⁰ The research was approved by the Ethics Committee of Hangzhou Normal University School of Public Health (20220009).²⁰ Informed consent was waived for the present study due to the retrospective study design. All participant details were de-identified and data from the initial health check-ups were included to perform a cross-sectional analysis based on scientific hypotheses. The study was performed according to the 1975 Helsinki Declaration, as revised in 2013.

The study design and methodology have been previously described in detail.²⁰ Briefly, participants were excluded from the study if they met any of the following criteria: (1) incomplete SUA data; (2) missing data for blood pressure, fasting blood glucose (FBG), and TC; or (3) history of hypertension, hyperglycemia, or hypercholesterolemia at the beginning of the study.²⁰ The reporting of this study conforms to the strengthening the reporting of observational studies in epidemiology (STROBE) guidelines.²²

Data extraction

Participants completed face-to-face interviews using standardized questionnaires that included demographic characteristics (age and gender) and medical history (hypertension, diabetes, dyslipidemia, and medication history). Weight and height were measured using calibrated scales and

height measuring devices. Blood pressure was assessed with a calibrated mercury sphygmomanometer. Venous blood samples were collected from all participants after at least an 8-h fast, and serum creatinine, SUA, FBG, and TC were measured using standard clinical laboratory methods, as previously described.²⁰

Definitions and outcomes

Hyperuricemia was defined as SUA $\geq 416 \mu\text{mol/L}$ for men, and SUA $\geq 357 \mu\text{mol/L}$ for women.²³ Hypercholesterolemia was defined as TC $\geq 6.22 \text{ mmol/L}$. Hypertension was defined as a systolic blood pressure (SBP) of $\geq 140 \text{ mmHg}$ or a diastolic blood pressure (DBP) of $\geq 90 \text{ mmHg}$, or having been diagnosed with hypertension and currently receiving antihypertensive treatment. Hyperglycemia is defined as FBG $\geq 7.0 \text{ mmol/L}$ or self-reported diabetes. Normal weight was defined as body mass index (BMI) 18.5 to $<24.0 \text{ kg/m}^2$, overweight was defined as BMI 24.0 to $<28.0 \text{ kg/m}^2$, and obese was defined as BMI $\geq 28 \text{ kg/m}^2$, in accordance with Chinese BMI categorization guidelines.²⁴ The exposure variable was SUA, and the outcome variable was TC.

Covariates

Possible confounding factors were evaluated utilizing descriptive statistics, clinical significance, and the number of outcome events.²⁰ The following variables were included in the analyses: age, sex, SBP, DBP, FBG, TC, creatinine, SUA and estimated glomerular filtration rate (eGFR).

Statistical analyses

Continuous variables are presented as mean \pm SD for data with normal distribution, or median and interquartile range (IQR) for data with skewed distribution. Histogram distribution, Q-Q plot, or

Kolmogorov-Smirnov test was used for determining whether variables were normally distributed. Differences between SUA groups were analyzed with χ^2 -test (for categorical data), one-way analysis of variance (ANOVA, for continuous data with normal distribution), or Kruskal–Wallis H-test (for continuous data with skewed distribution). The Bonferroni correction *P*-value was used for multiple comparisons.

The association between SUA and TC was evaluated using linear regression models (regression coefficients β and 95% confidence interval [CI]) with adjustment for major covariables. For analyses, SUA ($\mu\text{mol/L}$) was entered either as a categorical variable, with participants grouped into 5 quantiles according to SUA levels; or as a continuous variable (per 100 unit). Confounders were selected on the basis of clinical relevance, as described previously,²⁰ or their associations with the outcomes of interest, or a change in effect estimate $>10\%$ ($P < 0.05$). Unadjusted, minimally adjusted, and fully adjusted findings are presented in accordance with STROBE guidelines, as follows: Crude model, a non-adjusted crude model; Model 1, adjusted for sociodemographic characteristics (age); Model 2, adjusted for Model 1 plus covariates with $P < 0.05$ in the univariate model, including BMI, SBP, DBP, and FBG; and Model 3, adjusted for Model 2 plus additional variables based on previous literature,²⁰ including creatinine and eGFR. A restricted cubic spline model was applied to develop smooth curves to examine the possible nonlinear dose-response associations between SUA and TC. In this model, SUA was used as a continuous variable with four knots (5th, 35th, 65th and 95th). A two-piecewise regression model was utilized to calculate the threshold effect of SUA on TC in terms of the smoothing plot. Subgroup analyses were conducted by subgroup variables. Heterogeneity across

subgroups was tested by adding a term to the model, in which the two predictor variables are multiplied. A series of sensitivity analyses were conducted to evaluate the robustness of the findings. Firstly, the reliability of the results was validated using propensity score adjusted,²⁵ propensity score matching,²⁶ and the inverse probability of treatment weighting.²⁷ Secondly, if an interaction between different strata was found in the subgroup analysis, an additional correlation analysis was performed to confirm the consistency of the results with the main analysis.

Statistical analyses were conducted using R software, version 4.2.2 (The R Foundation; <http://www.R-project.org>) and Free Statistics software, version 1.9.2 (Free Clinical Medical Technology Co., Ltd, Beijing, China). Statistical significance was set at a two-sided *P* value < 0.05 .

Results

Characteristics of the participants

A total of 6119 adults were included in the study, of whom, 4078 (66.6%) were female. The baseline characteristics stratified by sex are shown in supplemental Table S1. The mean age of the female and male participants was 63.7 ± 9.0 and 69.8 ± 8.9 years, respectively. Men were older and had higher BMI, SBP, DBP, FBG, and SUA compared with the female population ($P < 0.001$). Women had greater mean TC than men (4.8 ± 0.7 and 4.5 ± 0.7 , respectively; $P < 0.001$), and higher creatinine levels ($P < 0.001$).

Participants of both sexes were divided into five groups based on increasing SUA levels (Q1–Q5, Table 1). Age, BMI, SBP, DBP, creatinine, TC and FBG all consistently showed positive trends in female participants, but as SUA levels increased from Q1 to Q5, eGFR consistently showed an inverse trend. A similar trend was observed

Table 1. Baseline characteristics of 6119 Chinese adults categorized according to sex and SUA levels.

Male participant subgroup according to SUA level (μmol/L)							
Variable	Total n = 2041	Q ₁ (≤283) n = 402	Q ₂ (284–326) n = 408	Q ₃ (327–367) n = 414	Q ₄ (368–415) n = 408	Q ₅ (≥416) n = 409	Statistical significance
Age, (years)	69.8 ± 8.9	67.6 ± 8.7	69.1 ± 8.8	70.1 ± 8.4	70.7 ± 8.9	71.7 ± 9.4	P < 0.001
BMI, (kg/m ²)	23.5 ± 3.0	22.8 ± 3.1	23.1 ± 2.8	23.3 ± 3.0	24.0 ± 3.1	24.5 ± 2.9	P < 0.001
SBP, (mmHg)	125.3 ± 9.8	123.3 ± 10.8	124.2 ± 9.8	125.9 ± 9.8	126.3 ± 9.0	126.7 ± 9.2	P < 0.001
DBP, (mmHg)	77.0 ± 6.7	76.7 ± 7.1	77.2 ± 6.9	76.8 ± 6.6	77.5 ± 6.4	77.1 ± 6.7	P = 0.483
FBG, (mmol/L)	5.4 ± 0.6	5.3 ± 0.6	5.4 ± 0.6	5.4 ± 0.6	5.4 ± 0.6	5.5 ± 0.6	P < 0.001
TC, (mmol/L)	4.5 ± 0.7	4.4 ± 0.7	4.5 ± 0.8	4.5 ± 0.7	4.6 ± 0.7	4.7 ± 0.7	P < 0.001
Creatinine, (μmol/L)	72.6 ± 13.8	72.4 ± 13.7	72.4 ± 14.3	72.2 ± 13.2	73.4 ± 13.7	72.6 ± 14.2	P = 0.752
eGFR, (mL/min/1.73 m ²)	83.4 ± 24.2	87.7 ± 24.9	86.8 ± 24.4	84.6 ± 23.4	83.0 ± 23.2	74.9 ± 23.0	P < 0.001
Female participant subgroup according to SUA level (μmol/L)							
Variable	Total n = 4078	Q ₁ (≤223) n = 811	Q ₂ (224–257) n = 819	Q ₃ (258–290) n = 806	Q ₄ (291–331) n = 813	Q ₅ (≥332) n = 829	Statistical significance
Age, (years)	63.7 ± 9.0	60.0 ± 8.9	62.3 ± 8.1	64.0 ± 8.7	64.8 ± 8.6	67.4 ± 9.1	P < 0.001
BMI, (kg/m ²)	23.1 ± 3.1	22.1 ± 2.8	22.5 ± 2.9	23.0 ± 3.0	23.5 ± 3.1	24.3 ± 3.1	P < 0.001
SBP, (mmHg)	123.0 ± 10.8	119.9 ± 11.4	121.7 ± 10.8	122.7 ± 10.7	124.3 ± 10.4	126.6 ± 9.4	P < 0.001
DBP, (mmHg)	74.4 ± 7.2	73.7 ± 7.5	74.2 ± 7.0	74.3 ± 7.0	74.8 ± 7.2	75.2 ± 6.9	P < 0.001
FBG, (mmol/L)	5.3 ± 0.6	5.2 ± 0.6	5.2 ± 0.5	5.3 ± 0.6	5.3 ± 0.6	5.4 ± 0.6	P < 0.001
TC, (mmol/L)	4.8 ± 0.7	4.6 ± 0.7	4.7 ± 0.7	4.8 ± 0.7	4.9 ± 0.7	4.9 ± 0.7	P < 0.001
Creatinine, (μmol/L)	76.0 ± 16.4	74.7 ± 15.0	74.0 ± 14.9	74.5 ± 16.0	76.8 ± 16.3	79.9 ± 18.5	P < 0.001
eGFR, (mL/min/1.73 m ²)	89.8 ± 28.0	96.9 ± 29.1	93.2 ± 26.8	91.1 ± 28.5	87.1 ± 27.0	80.8 ± 26.0	P < 0.001

Data presented as mean ± SD.
SUA, serum uric acid; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; eGFR, estimated glomerular filtration rate.

in male participants, but there was no statistically significant trend between SUA level and DBP or creatinine ($P > 0.05$).

Association between SUA level and TC

The results of univariate linear regression analysis (Table 2) showed that TC was strongly positively correlated with age, BMI, SBP, DBP, FBG, eGFR and SUA in women ($P < 0.05$), but TC and creatinine showed an inverse association. A similar trend was observed in men, however, SBP and creatinine were not associated with TC ($P > 0.05$).

In multivariable linear regression analyses (Table 3), SUA expressed as a continuous variable (per 100 unit) increased in association with TC in men ($\beta = 0.09$; 95% CI 0.15, 0.14; $P < 0.001$) and in women ($\beta = 0.13$; 95% CI 0.10, 0.17; $P < 0.001$), independent of potential confounders. As a categorical variable, the Q5 group exhibited higher TC levels than the Q1 group in men ($\beta = 0.26$; 95% CI 0.16, 0.37; $P < 0.001$) and in women ($\beta = 0.25$; 95% CI 0.17, 0.32; $P < 0.001$; Table 3, model 3).

Nonlinear relationship between SUA and TC in females

In male participants, multivariate smooth splines analysis showed that the nonlinear relationship between SUA and TC was not found to be statistically significant (P for nonlinearity = 0.969, Figure 1(a)). However, in female participants, an inverted L-shaped relationship was revealed between SUA and TC (P for nonlinearity = 0.004, Figure 1(b)). When SUA levels were $< 359.962 \mu\text{mol/L}$, TC levels increased with rising SUA, and the correlation coefficient (β) for TC was 0.002 (95% CI 0.001, 0.002; Table 4).

Subgroup analyses

Subgroup analyses revealed significant interactions between age and SUA in female participants ($P < 0.05$; Figure 2). However, no interaction was shown between age, BMI and SUA levels in males (Figure 3).

Sensitivity analyses

In the sensitivity analyses, propensity score matching was used to adjust for baseline

Table 2. Univariate linear regression analyses evaluating the association between demographic and clinical variables and total cholesterol in 6119 Chinese adults categorized according to sex.

Variable	Male participants (n = 2041)			Female participants (n = 4078)		
	β (95% CI)	Statistical significance (t-test)	Statistical significance (F-test)	β (95% CI)	Statistical significance (t-test)	Statistical significance (F-test)
Age, (years)	-0.006 (-0.009, -0.002)	$P = 0.0017$	$P = 0.0017$	0.01 (0.008, 0.013)	$P < 0.001$	$P < 0.001$
BMI, (kg/m ²)	0.024 (0.014, 0.035)	$P < 0.001$	$P < 0.001$	0.014 (0.006, 0.021)	$P < 0.001$	$P < 0.001$
SBP, (mmHg)	0 (-0.003, 0.003)	$P = 0.9948$	$P = 0.9948$	0.005 (0.003, 0.007)	$P < 0.001$	$P < 0.001$
DBP, (mmHg)	0.01 (0.005, 0.015)	$P < 0.001$	$P < 0.001$	0.006 (0.003, 0.009)	$P < 0.001$	$P < 0.001$
FBG, (mmol/L)	0.144 (0.092, 0.195)	$P < 0.001$	$P < 0.001$	0.165 (0.126, 0.205)	$P < 0.001$	$P < 0.001$
Creatinine, ($\mu\text{mol/L}$)	0.001 (-0.002, 0.003)	$P = 0.6637$	$P = 0.6637$	-0.001 (-0.003, 0)	$P = 0.0361$	$P = 0.0361$
eGFR, (mL/min/1.73 m ²)	0.003 (0.002, 0.005)	$P < 0.001$	$P < 0.001$	0.002 (0.001, 0.003)	$P < 0.001$	$P < 0.001$
Uric acid, ($\mu\text{mol/L}$)	0.001 (0, 0.001)	$P < 0.001$	$P < 0.001$	0.002 (0.001, 0.002)	$P < 0.001$	$P < 0.001$

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; eGFR, estimated glomerular filtration rate; CI, confidence interval.

Table 3. Multivariable linear regression analyses of SUA and clinical outcomes in 6119 Chinese adults categorized according to sex and SUA levels.

Outcome	Crude model			Model 1			Model 2			Model 3		
	β (95% CI)	Statistical significance		β (95% CI)	Statistical significance		β (95% CI)	Statistical significance		β (95% CI)	Statistical significance	
Male participants ($n = 2041$)												
Per 100 unit SUA	0.09 (0.05, 0.13)	$P < 0.001$		0.1 (0.06, 0.14)	$P < 0.001$		0.08 (0.04, 0.12)	$P < 0.001$		0.09 (0.05, 0.14)	$P < 0.001$	
Q ₁ (131–283)	0 (Ref)			0 (Ref)			0 (Ref)			0 (Ref)		
Q ₂ (284–326)	0.09 (–0.02, 0.19)	$P = 0.095$		0.1 (0, 0.2)	$P = 0.059$		0.08 (–0.02, 0.18)	$P = 0.106$		0.08 (–0.02, 0.18)	$P = 0.104$	
Q ₃ (327–367)	0.11 (0, 0.21)	$P = 0.042$		0.12 (0.02, 0.23)	$P = 0.017$		0.11 (0.01, 0.21)	$P = 0.038$		0.11 (0.01, 0.21)	$P = 0.027$	
Q ₄ (368–415)	0.13 (0.03, 0.23)	$P = 0.012$		0.15 (0.05, 0.26)	$P = 0.003$		0.12 (0.02, 0.22)	$P = 0.023$		0.13 (0.03, 0.23)	$P = 0.014$	
Q ₅ (≥ 416)	0.25 (0.14, 0.35)	$P < 0.001$		0.28 (0.17, 0.38)	$P < 0.001$		0.23 (0.12, 0.33)	$P < 0.001$		0.26 (0.16, 0.37)	$P < 0.001$	
P for trend		$P < 0.001$			$P < 0.001$			$P < 0.001$			$P < 0.001$	
Female participants ($n = 4078$)												
Per 100 unit SUA	0.16 (0.13, 0.2)	$P < 0.001$		0.13 (0.1, 0.17)	$P < 0.001$		0.11 (0.08, 0.15)	$P < 0.001$		0.13 (0.1, 0.17)	$P < 0.001$	
Q ₁ (92–223)	0 (Ref)			0 (Ref)			0 (Ref)			0 (Ref)		
Q ₂ (224–257)	0.11 (0.04, 0.18)	$P = 0.003$		0.09 (0.02, 0.16)	$P = 0.012$		0.08 (0.01, 0.16)	$P = 0.018$		0.09 (0.02, 0.16)	$P = 0.014$	
Q ₃ (258–290)	0.23 (0.15, 0.3)	$P < 0.001$		0.19 (0.12, 0.27)	$P < 0.001$		0.18 (0.1, 0.25)	$P < 0.001$		0.18 (0.11, 0.26)	$P < 0.001$	
Q ₄ (291–331)	0.3 (0.23, 0.37)	$P < 0.001$		0.26 (0.19, 0.34)	$P < 0.001$		0.24 (0.17, 0.31)	$P < 0.001$		0.26 (0.19, 0.33)	$P < 0.001$	
Q ₅ (≥ 332)	0.31 (0.24, 0.38)	$P < 0.001$		0.25 (0.18, 0.32)	$P < 0.001$		0.21 (0.13, 0.28)	$P < 0.001$		0.25 (0.17, 0.32)	$P < 0.001$	
P for trend		$P < 0.001$			$P < 0.001$			$P < 0.001$			$P < 0.001$	

Crude model was unadjusted. Model 1 was adjusted for age. Model 2 was adjusted for model 1 plus BMI, SBP, DBP and FBG. Model 3 was adjusted for model 1 plus model 2 plus creatinine and eGFR.
SUA, serum uric acid; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; eGFR, estimated glomerular filtration rate; CI, confidence interval.




Figure 1. Results of multivariate smoothing splines analysis, showing: (a) linear relationship between SUA and TC in male participants; and (b) nonlinear relationship between SUA and TC in female participants. Adjustment factors included age, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, creatinine and estimated glomerular filtration rate, respectively. Only 99% of the data are shown. The red line and pink area represent estimated values and corresponding 95% confidence intervals, respectively. SUA, serum uric acid; TC, total cholesterol.

Table 4. Linear regression models to analyze threshold effects of SUA and TC in 4078 Chinese female adults.

SUA, $\mu\text{mol/L}$	β	(95% CI)	Statistical significance
<359.962	0.002	(0.001, 0.002)	$P < 0.001$
≥ 359.962	0.001	(-0.001, 0.002)	$P = 0.522$
Likelihood ratio test			$P = 0.047$

Adjustment factors included age, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, creatinine and estimated glomerular filtration rate.
SUA, serum uric acid; TC, total cholesterol; CI, confidence interval.

characteristics, and correlation analysis was performed.

After propensity score matching, 407 pairs from each group of male participants, and 533 pairs from each group of female participants, were well matched (supplemental Table S2), with no statistically

significant differences between the two matched groups.

Both univariate and multivariable linear regression analyses, as well as propensity score adjusted, propensity score matched and inverse probability of treatment weighting, revealed a significantly higher incidence of TC in male and female participants with hyperuricemia. For both sexes, the coefficients (β) were $P < 0.05$ and varied between 0.16 and 0.21 for males, and 0.11 and 0.20 for females (Table 5).

A further sensitivity analysis was conducted in female participants aged < 60 years. In multivariable linear regression analyses, SUA expressed as a continuous variable (per 100 unit) was increased in association with TC ($\beta = 0.22$; 95% CI 0.16, 0.28; $P < 0.001$). As a categorical variable, the Q5 group exhibited higher TC levels ($\beta = 0.36$; 95% CI 0.24, 0.48; $P < 0.001$) than the Q1 group (supplemental Table S3, model 3).




Figure 2. Subgroup analysis of relationships between SUA and TC in female participants grouped into 5 quantiles according to increasing SUA level (Q1–Q5). Coefficient (β) adjusted for age, BMI, systolic blood pressure, diastolic blood pressure, fasting blood glucose, creatinine and estimated glomerular filtration rate, respectively. BMI, body mass index; CI, confidence interval; SUA, serum uric acid ($\mu\text{mol/L}$); TC, total cholesterol.




Figure 3. Subgroup analysis of relationships between SUA and TC in male participants grouped into 5 quantiles according to increasing SUA level (Q1–Q5). Coefficient (β) adjusted for age, BMI, systolic blood pressure, diastolic blood pressure, fasting blood glucose, creatinine and estimated glomerular filtration rate, respectively. BMI, body mass index; CI, confidence interval; SUA, serum uric acid ($\mu\text{mol/L}$); TC, total cholesterol.

Table 5. Associations between hyperuricemia and outcome in the crude analysis, multivariable analysis, and propensity-score analyses.

Group	Male		Female	
Normal SUA	407/1633		533/3533	
Hyperuricemia	407/409		533/545	
Analysis	β (95% CI)	Statistical significance	β (95% CI)	Statistical significance
Unmatched crude	0.16 (0.08, 0.24)	$P < 0.001$	0.17 (0.11, 0.24)	$P < 0.001$
Multivariable adjusted	0.18 (0.1, 0.26)	$P < 0.001$	0.11 (0.04, 0.18)	$P = 0.002$
Propensity Score adjusted	0.19 (0.11, 0.27)	$P < 0.001$	0.13 (0.06, 0.2)	$P < 0.001$
Propensity Score Matched	0.21 (0.11, 0.32)	$P < 0.001$	0.11 (0.02, 0.2)	$P = 0.016$
Weighted IPTW	0.18 (0.09, 0.26)	$P < 0.001$	0.2 (0.14, 0.27)	$P < 0.001$

Data presented as *n* prevalence.

Participants were divided into a normal serum uric acid group and hyperuricemia group according to the following cut-off values: men, $\geq 416 \mu\text{mol/L}$; women $\geq 357 \mu\text{mol/L}$, followed by propensity-score analyses.

SUA, serum uric acid; IPTW, inverse probability of treatment weighting.

Discussion

The present study revealed a consistently positive correlation between TC and SUA in male and female adult groups, which remained after adjusting for confounders. In females, there was an inverted L-shaped relationship between SUA and TC, with a cut-off value of $359.962 \mu\text{mol/L}$. SUA and TC in men exhibited a linear association. Subgroup analysis revealed that, while there was an interaction in the age stratification ($P < 0.05$) for women, there were no significant interactions for men. Sensitivity analysis showed a robust and consistent correlation between SUA and TC. These observations have important implications for current TC management strategies, particularly for the Chinese population.

The relationship between SUA and dyslipidemia has yielded inconsistent results. Li et al.²⁸ found no association between SUA and various blood lipid parameters in obese individuals. However, Choe et al.²⁹ indicated that hyperuricemia is a risk factor for abnormal blood lipid levels. The present study found an independent correlation

between SUA levels and TC. For lipid subtypes, a cross-sectional study of data from the USA National Health and Nutrition Examination Survey showed a positive correlation between hyperuricemia and high triglycerides.¹⁶ In another study, abnormal levels of triglycerides and low-density lipoprotein cholesterol (LDL-C) were found to be positively correlated with SUA levels.³⁰ Similarly, Kuwabara et al.³¹ identified a connection between elevated SUA levels and both LDL-C and triglycerides, and an analysis of data from the China Hainan centenarian cohort study (CHCCS) also found similar results.¹⁷ Previous studies have concentrated on the relationships among LDL-C, triglycerides and SUA, but they have not addressed the overall effect of TC on SUA or the gender differences related to both. Although Luo et al.²⁰ found gender differences in the relationship between SUA levels and TC, they did not identify specific dose-response relationships between the two. The present study addresses this gap.

Regarding the dose-response relationship between SUA and dyslipidemia, a non-linear dose response among the general

population has been previously described for triglycerides, LDL-C, and SUA, without exhibiting gender differences.²¹ In addition, another study reported an inverse U-shaped association between SUA and high LDL-C.³² The present study revealed an inverted L-shaped relationship between SUA and TC with a cut-off SUA value of 359.962 $\mu\text{mol/L}$ in women, whereas a linear relationship was shown in men. In contrast, Kuwabara et al.³³ found a J-shaped association between SUA and dyslipidemia in both men and women. The optimal range of SUA for dyslipidemia was approximately 2–5 mg/dL in men and 1–4 mg/dL in women. Similar results have been reported elsewhere.³⁴ Differences between the present findings and those of previously reported studies may be related to variations in genetic factors and socioeconomic status.

Regarding the gender strength of the relationship between SUA and dyslipidemia, Lin et al.¹⁹ found that the correlation between high triglycerides and LDL-C with SUA levels was significant only in men and not in women. Conversely, another study suggested that the relationship between SUA levels and dyslipidemia seems to be more significant in women,³⁵ which appears to concur with the present finding of a significantly stronger association between SUA and TC in women than in men. The gender differences between SUA and TC may be influenced by estrogen,^{36,37} which affects SUA excretion, the levels and activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and the expression of estrogen receptor alpha. Additionally, these significant gender differences offer important insights for managing and controlling SUA and TC, providing great hope for future prevention strategies and treatment approaches.

A study among menopausal women found that those with hyperuricemia showed significantly higher levels of triglycerides and LDL-C.³⁸ In the present

subgroup analysis, an interaction between SUA and TC was identified across age-stratified groups, with a linear positive correlation observed between SUA and TC in women under 60 years-of-age. Comparable findings have been reported in previous studies.³⁹

The present study has several strengths. Firstly, the sample size was large enough to provide strong evidence for gender differences. Secondly, the study extends the association between SUA and TC to the general population. However, the present results may be limited by several factors. Firstly, the study was cross-sectional in design, thus, it is not possible to establish a causal relationship between SUA and TC. Further cohort studies are needed to clarify the relationship between SUA and TC. Secondly, the single-center and retrospective nature of the study may have resulted in selection bias. Thirdly, despite employing regression models, stratified analyses, and sensitivity analyses to adjust for potential confounders, residual confounding effects from unmeasured or unknown variables may still persist.

Conclusions

A significant gender difference was found in the association between uric acid and total cholesterol. A reverse L-shaped relationship between SUA and TC was found in adult females, while in males, a linear relationship was shown. Additionally, the association between SUA and TC was shown to be significantly stronger in females than in males.

Acknowledgements

We appreciate Dr. Jie Liu of the Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital for statistics, study design consultations and editing the manuscript.

Author contributions

LG designed the study, performed the primary research, and wrote the manuscript. LC

supported manuscript revision. LC, LH, and YZ supported the data collection and analysis. All authors read and approved the final manuscript.

Data availability statement

The datasets used and analyzed during the current study are available at Dryad (<https://doi.org/10.5061/dryad.z08kprrk1>).

Declaration of conflicting interest

The authors declare that there is no conflict of interest.


Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Supplementary material

Supplemental material for this article is available online.

ORCID iD

Leilei Guo  <https://orcid.org/0009-0005-3404-2115>

References

1. Bhatnagar D, Soran H and Durrington PN. Hypercholesterolaemia and its management. *BMJ* 2008; 337: a993.
2. Crea F. Targeting hypercholesterolaemia: challenges and opportunities. *Eur Heart J* 2023; 44: 2263–2266.
3. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. *N Engl J Med* 2007; 356: 2388–2398.
4. Song PK, Man QQ, Li H, et al. Trends in lipids level and dyslipidemia among Chinese adults, 2002–2015. *Biomed Environ Sci* 2019; 32: 559–570.
5. Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management. *Front Pharmacol* 2023; 14: 1190934.
6. Pan L, Yang Z, Wu Y; China National Survey of Chronic Kidney Disease Working Group, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. *Atherosclerosis* 2016; 248: 2–9.
7. Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications. *Nat Rev Cardiol* 2019; 16: 203–212.
8. El Ridi R and Tallima H. Physiological functions and pathogenic potential of uric acid: a review. *J Adv Res* 2017; 8: 487–493.
9. Campion EW, Glynn RJ and DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. *Am J Med* 1987; 82: 421–426.
10. Liu R, Han C, Wu D, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis. *Biomed Res Int* 2015; 2015: 762820.
11. Huang J, Ma ZF, Zhang Y, et al. Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis. *Glob Health Res Policy* 2020; 5: 52.
12. Tian T, Wang Y, Xie W, et al. Associations of serum uric acid with clustering of cardiovascular risk factors and a 10-year atherosclerotic cardiovascular disease risk score in Jiangsu adults, China. *Diabetes Metab Syndr Obes* 2021; 14: 3447–3460.
13. Li W, Wang Y, Ouyang S, et al. Association between serum uric acid level and carotid atherosclerosis and metabolic syndrome in patients with type 2 diabetes mellitus. *Front Endocrinol (Lausanne)* 2022; 13: 890305.
14. Pang S, Jiang Q, Sun P, et al. Hyperuricemia prevalence and its association with metabolic disorders: a multicenter retrospective real-world study in China. *Ann Transl Med* 2021; 9: 1550.
15. Yu J, Liu X, Ji H, et al. Distribution of serum uric acid concentration and its association with lipid profiles: a single-center retrospective study in children aged 3 to 12 years with adenoid and tonsillar hypertrophy. *Lipids Health Dis* 2023; 22: 48.
16. Tan MY, Mo CY, Li F, et al. The association between serum uric acid and hypertriglyceridemia: evidence from the National Health and Nutrition Examination survey (2007–2018). *Front Endocrinol (Lausanne)* 2023; 14: 1215521.

17. Kou F, Yang S, Wang S, et al. Association between serum uric acid and major chronic diseases among centenarians in China: based on the CHCCS study. *BMC Geriatr* 2021; 21: 231.
18. Fu YQ, Yang H, Zheng JS, et al. Positive association between metabolic syndrome and serum uric acid in Wuhan. *Asia Pac J Clin Nutr* 2017; 26: 343–350.
19. Lin YK, Lin YP, Lee JT, et al. Sex-specific association of hyperuricemia with cardiometabolic abnormalities in a military cohort: the CHIEF study. *Medicine (Baltimore)* 2020; 99: e19535.
20. Luo Y, Wu Q, Meng R, et al. Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in southeastern China. *BMJ Open* 2023; 13: e073930.
21. Xu Y, Dong H, Zhang B, et al. Association between dyslipidaemia and the risk of hyperuricaemia: a six-year longitudinal cohort study of elderly individuals in China. *Ann Med* 2022; 54: 2402–2410.
22. Von Elm E, Altman DG, Egger M; STROBE Initiative, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147: 573–577.
23. Shan R, Ning Y, Ma Y, et al. Incidence and risk factors of hyperuricemia among 2.5 million Chinese adults during the years 2017–2018. *Int J Environ Res Public Health* 2021; 18: 2360.
24. Weng J, Ji L, Jia W; Chinese Diabetes Society, et al. Standards of care for type 2 diabetes in China. *Diabetes Metab Res Rev* 2016; 32: 442–458.
25. Andrew BY, Alan Brookhart M, Pearse R, et al. Propensity score methods in observational research: brief review and guide for authors. *Br J Anaesth* 2023; 131: 805–809.
26. Elze MC, Gregson J, Baber U, et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. *J Am Coll Cardiol* 2017; 69: 345–357.
27. Bettega F, Mendelson M, Leyrat C, et al. Use and reporting of inverse-probability-of-treatment weighting for multicategory treatments in medical research: a systematic review. *J Clin Epidemiol* 2024; 170: 111338.
28. Li L, Song Q and Yang X. Lack of associations between elevated serum uric acid and components of metabolic syndrome such as hypertension, dyslipidemia, and T2DM in overweight and obese Chinese adults. *J Diabetes Res* 2019; 2019: 3175418.
29. Choe JH, Bang KS and Jang SY. Factors affecting dyslipidemia among Korean adolescents: an analysis using the 8th Korea National Health and Nutrition Examination survey (2021). *Children (Basel)* 2023; 10: 1618.
30. Son M, Seo J and Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea national health and nutrition examination survey 2016–2017. *PLoS One* 2020; 15: e0228684.
31. Kuwabara M, Borghi C, Cicero AFG, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. *Int J Cardiol* 2018; 261: 183–188.
32. Peng L, Liu L, Ma N, et al. The dose-response relationship of serum uric acid with dyslipidaemia and its components: a cross-sectional study of a Chinese multi-ethnic cohort. *Lipids Health Dis* 2022; 21: 36.
33. Kuwabara M, Hisatome I, Niwa K, et al. The optimal range of serum uric acid for cardiometabolic diseases: a 5-year Japanese cohort study. *J Clin Med* 2020; 9: 942.
34. Kawasoe S, Kubozono T, Salim AA, et al. J-shaped association between serum uric acid levels and the prevalence of a reduced kidney function: a cross-sectional study using Japanese health examination data. *Intern Med* 2024; 63: 1539–1548.
35. Tao M, Pi X, Ma X, et al. Relationship between serum uric acid and clustering of cardiovascular disease risk factors and renal disorders among shanghai population: a multicentre and cross-sectional study. *BMJ Open* 2019; 9: e025453.
36. Yahyaoui R, Esteva I, Haro-Mora JJ, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. *J Clin Endocrinol Metab* 2008; 93: 2230–2233.

37. Pellegrini M, Pallottini V, Marin R, et al. Role of the sex hormone estrogen in the prevention of lipid disorder. *Curr Med Chem* 2014; 21: 2734–2742.
38. Dobrzyńska M and Przysławski J. The relationship between serum uric acid concentration and cardiovascular risk factors in normotensive postmenopausal women with dyslipidemia. *Acta Sci Pol Technol Aliment* 2020; 19: 123–131.
39. Cota E Souza LA, D'Angelo Gc de O, Da Silva GN, et al. Uric acid level in climacteric women and its association with clinical and metabolic parameters. *Sci Rep* 2023; 13: 8475.